Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Futura Medical ( (GB:FUM) ) has issued an announcement.
Futura Medical has reported highly positive early feasibility results for WSD4000, its topical gel prototype for female sexual dysfunction, in a 12-patient study that showed statistically and clinically significant improvements on the Female Sexual Function Index, including arousal, lubrication, pain, orgasm and satisfaction, in both pre- and post-menopausal women. The data, which also demonstrated rapid onset of genital sensation, strong performance across Female Sexual Encounter Profile metrics and good tolerability, gives the company confidence to advance WSD4000 into a sham/placebo-controlled sensory study and a 200-subject home-use trial during 2026, positioning Futura to develop what could be the first regulatory-approved over-the-counter treatment for female sexual dysfunction and potentially expand its presence in a large, chronically underserved global market.
The most recent analyst rating on (GB:FUM) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Spark’s Take on GB:FUM Stock
According to Spark, TipRanks’ AI Analyst, GB:FUM is a Neutral.
The score is held back most by the earnings call’s sharply reduced FY2025 outlook and short cash runway, plus weak technical trend signals. These risks are partially offset by the FY2024 profitability turnaround and a zero-debt balance sheet, though negative free cash flow keeps financial quality mixed.
To see Spark’s full report on GB:FUM stock, click here.
More about Futura Medical
Futura Medical plc is a UK-based consumer healthcare group specialising in the research, development and global commercialisation of innovative, topically delivered gel formulations for sexual health. Its lead over-the-counter product Eroxon is a topical gel for erectile dysfunction, supported by distribution partnerships in major markets including the US and Europe, while pipeline products such as WSD4000 and Eroxon Intense target underserved segments in female and male sexual dysfunction.
Average Trading Volume: 7,220,802
Technical Sentiment Signal: Sell
Current Market Cap: £7.59M
For detailed information about FUM stock, go to TipRanks’ Stock Analysis page.